GC Biopharma's Phase 3 Clinical Trial Results for Hunterase Published in SCIE-Indexed Journal
Conducted at Samsung Medical Center, the Phase 3 clinical trial enrolled 24 newly diagnosed Hunter Syndrome patients with no prior treatment. It evaluated the efficacy and safety of Hunterase over a one-year treatment period.
Hunter Syndrome is a rare genetic disorder caused by a deficiency of iduronate-2-sulfatase (IDS), an enzyme critical for glycosaminoglycan (GAG) catabolism. This deficiency leads to the progressive accumulation of GAGs in various organs and tissues, resulting in multisystemic dysfunction, including joint stiffness and hepatosplenomegaly.
The clinical trial results demonstrated that Hunterase significantly enhanced functional mobility, reduced urinary GAG concentrations, and markedly alleviated hepatosplenomegaly.
In the 6-Minute Walk Test (6-MWT), the primary endpoint of the study, patients treated with Hunterase walked an average of 62.2 meters more after treatment. This improvement was more than eight times greater compared to the placebo group, which saw an average increase of just 7.3 meters.
The 6-MWT measures the distance a patient can walk on a flat surface within 6 minutes. It is a widely used clinical measure for evaluating functional mobility, cardiopulmonary function, muscle strength, and overall physical health. In the context of Hunter syndrome, it serves as a standardized and meaningful indicator of disease progression and quality of life.
In addition to the primary endpoint, the study also achieved positive outcomes in secondary endpoints, including changes in urinary total glycosaminoglycan (GAG) levels, as well as heparan sulfate (HS) and dermatan sulfate (DS) levels. The GAG levels decreased by 71%, while HS and DS levels decreased by 89% and 88%, respectively. Moreover, liver and spleen volumes were reduced by 27% and 26%, respectively, demonstrating the drug's effectiveness in addressing organ enlargement commonly associated with the disease.
Hunterase also demonstrated a favorable safety profile. Most adverse events were mild or moderate, and no patients discontinued treatment due to side effects. Notably, only 19% of the patients had neutralizing antibodies detected three or more consecutive times, which is significantly lower than the 62.5% observed with the existing treatments. This suggests that Hunterase may offer a more sustained therapeutic effect compared to other currently available therapy.
"This clinical trial is especially meaningful as it represents the first Phase 3 study in Asian patients to validate the clinical efficacy of Hunterase", said Professor Young Bae Sohn of Ajou University School of Medicine and Ajou University Hospital, the journal's first author. "The results showed significant clinical improvement not only in metabolic markers but also in organ size normalization and restoration of physical mobility."
"We are thrilled to publish our encouraging phase 3 clinical trial results", stated Jae Uk Jeong, Head of R&D at GC Biopharma. "Hunterase, developed in Korea using our proprietary technology, has the potential to significantly improve the lives of patients with Hunter syndrome."
Hunter Syndrome is an X-linked lysosomal storage disorder, affecting approximately 1 in 100,000 male births. In severe cases, the patients experience early death before they reach adulthood, highlighting the need for early diagnosis and treatment. Currently, two treatments are widely available worldwide for Hunter Syndrome: GC Biopharma's Hunterase and Takeda's Elaprase.
About GC Biopharma
GC Biopharma (formerly known as Green Cross Corporation) is a biopharmaceutical company headquartered in Yong-in, South Korea. The company has over half a century of experience in the development and manufacturing of plasma derivatives and vaccines, and is expanding its global presence with successful US market entry of Alyglo™(intravenous immunoglobulin G) in 2024. In line with its mission to meet the demands of future healthcare, GC Biopharma continues to drive innovation by leveraging its core R&D capabilities in engineering of proteins, mRNAs, and lipid nanoparticle (LNP) drug delivery platform to develop therapeutics for the field of rare disease as well as I&I (Immunology & Inflammation). To learn more about the company, visit https://www.gcbiopharma.com/eng/
This press release may contain biopharmaceuticals in forward-looking statements, which express the current beliefs and expectations of GC Biopharma's management. Such statements do not represent any guarantee by GC Biopharma or its management of future performance and involve known and unknown risks, uncertainties, and other factors. GC Biopharma undertakes no obligation to update or revise any forward-looking statement contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
6 hours ago
- Korea Herald
Eviva Partners Launches New Think Tank, Exposes Attack on Aluminum-Containing Vaccines
NEW YORK, July 31, 2025 /PRNewswire/ -- Eviva Partners, a nonprofit organization dedicated to strengthening public understanding of medical evidence, is proud to announce the launch of Protecting Our Health (POH), a new think tank that brings together international experts in communication, public health and misinformation to confront the rise of pseudoscience. "Medical research has generated a tremendous number of evidence-based interventions, but these are not universally adopted, leading to gaps in care," said Eviva CEO and founder Alex Morozov, a physician-scientist, writer and former pharmaceutical executive. "Our goal is to empower people to make evidence-based decisions. This is more important now than ever. POH was launched to counteract the assault on science and health — and to reach people before deceptive tactics take hold." Eviva and POH are grounded in three principles: On Sunday, MSNBC published an op-ed by Morozov, leading vaccinologist Dr. Helen Petousis-Harris and Eviva board member Professor Stephan Lewandowsky. "Robert F. Kennedy Jr. and others … appear to be orchestrating a strategic attack on aluminum-containing vaccines," the op-ed says. But the science does not support aluminum as the culprit. In a major new study involving more than 1.2 million children, Danish researchers found no link between aluminum in vaccines and 50 chronic diseases, including autism. The op-ed warns: "If anti-vaccine activists successfully undermine aluminum-containing vaccines despite research findings like the Danish study, the consequences will be catastrophic. Vaccine-preventable diseases — such as diphtheria, meningitis, hepatitis and cancers of the liver, cervix and penis — will bounce back, causing tremendous death and suffering. And rates of autism will remain unchanged, as they have for decades." Protecting Our Health is not just a campaign. It is a call to action. By combining evidence, storytelling and community engagement, Eviva and POH seek to undo the damage caused by misinformation and chart a path forward — one rooted in evidence, empowerment and health for all.
Korea Herald
6 hours ago
- Korea Herald
OSR Holdings Provides Strategic Update on Woori IO Term Sheet and Share Exchange Structure
BELLEVUE, Wash. and SEOUL, South Korea, July 31, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company advancing biomedical and wellness innovation, today issued a strategic update regarding its recently announced Term Sheet with Woori IO Co., Ltd. ("WORIO"), a South Korean medical device company pioneering noninvasive glucose monitoring technology. The transaction, once completed, will result in WORIO becoming a wholly owned subsidiary of OSR Holdings Co., Ltd. ("OSRK"), a Korean affiliate of OSRH. As previously disclosed, WORIO shareholders will receive newly issued OSRK shares, along with a conditional right to exchange those shares for OSRH common stock if OSRH's share price reaches $10.00 or more within three years from the signing of the Term Sheet. WORIO Shareholders Align with OSRH Upside The company emphasizes that the $10 OSRH share condition is intended as a performance-aligned incentive, reflecting WORIO shareholders' long-term confidence in OSRH's growth potential. Rather than requesting immediate liquidity, the Sellers — WORIO's shareholders — have agreed to convert their OSRK shares into OSRH shares only upon OSRH reaching $10.00 per share, representing a nearly 10x premium over recent trading levels. "This is not a dilution event, but a strong vote of confidence," said Peter Hwang, CEO of OSR Holdings. "WORIO's shareholders are betting on our ability to realize transformative value and are choosing to stay aligned with OSRH shareholders for the long term. That alignment is a positive signal for the market." If OSRH's share price does not meet the $10.00 threshold within three years, the conversion will not occur, and WORIO shareholders will remain equity holders in the privately held OSRK entity. The companies have agreed to renegotiate in good faith at that time, if necessary. Noninvasive Glucose Monitoring: A Transformational Market The strategic rationale behind the transaction lies in the tremendous unmet need and market potential for noninvasive glucose monitoring. Today's global CGM (continuous glucose monitoring) market — dominated by companies like Dexcom and Abbott — still relies on minimally invasive sensors that require skin penetration or consumables. WORIO's technology leverages near-infrared spectroscopy (NIRS) to deliver accurate, needle-free glucose measurement. This makes it well suited for integration into wearable devices such as smartwatches. The company has already completed a proof-of-concept study at Korea University Hospital and is now preparing for a larger confirmatory study for regulatory approval in Korea. "WORIO gives OSRH a unique opportunity to enter this global market before the technology reaches commercial maturity," added Mr. Hwang. "This transaction positions our shareholders to benefit from a future that could redefine diabetes management — without the burden of invasive devices." Industry Landscape and Strategic Positioning According to industry reports, the global blood glucose monitoring device market is projected to exceed $40 billion by 2030, with strong tailwinds from rising diabetes prevalence and increasing demand for painless, real-time monitoring. "Imagine the difference this technology could make for individuals who face the daily burden of monitoring blood glucose and navigating the complexity of current invasive devices," said Dr. Constance Höfer, CSO of OSRH. "Beyond the clear advantages for patients and their caregivers, this new non-invasive device could also generate valuable novel datasets—for example, in patients at early stages of metabolic syndrome, studies on cancer relapse and the benefits of exercise, or research exploring the effects of pre- and probiotics on human health and the optimization of elite athletic performance." To date, no company worldwide has received regulatory approval for truly noninvasive glucose monitoring. Media coverage of startups like Afon Technology in Europe underscore the growing interest and momentum in this field, yet few players have established both a working prototype and a regulatory engagement plan. WORIO represents one of the rare companies globally to meet both criteria — and OSRH is positioned as an early acquirer ahead of full commercialization. In Q1 2025, WORIO was selected to participate in Samsung Electronics' innovative startup program, C-Lab Outside. Next Steps Under the 6-month exclusivity period set forth in the Term Sheet, OSRH will continue confirmatory legal, financial, and technical due diligence, with a target to execute definitive agreements within that window. The company looks forward to further engaging with investors as this transaction develops. About OSR Holdings, Inc. OSR Holdings, Inc. (NASDAQ: OSRH) is a global healthcare holding company dedicated to advancing biomedical innovation approaches to health and wellness. Through its subsidiaries, OSRH is engaged in immuno-oncology, regenerative biologics, and medical device technologies. Its vision is to build a portfolio of breakthrough healthcare solutions to improve global health outcomes. Learn more at About Woori IO Co., Ltd. Woori IO is a South Korea-based medical device company developing noninvasive biosensing technologies for glucose monitoring and beyond. Its proprietary NIRS-based system enables accurate, pain-free glucose tracking and is designed for integration into wearables. Visit for more information. Forward-Looking Statements This press release contains forward-looking statements, including expectations regarding the proposed acquisition of Woori IO, future stock performance, regulatory approvals, and market potential. These statements are based on current assumptions and involve risks and uncertainties that could cause actual results to differ materially. OSR Holdings undertakes no obligation to update these statements except as required by law.
Korea Herald
6 hours ago
- Korea Herald
FROM THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2025: SNAP BENEFITS LINKED TO SLOWER COGNITIVE DECLINE, 10-YEAR STUDY FINDS
Key Takeaways TORONTO, July 30, 2025 /PRNewswire/ -- People who participated in the U.S. Supplemental Nutrition Assistance Program (SNAP) had slower cognitive decline over 10 years than those who didn't participate, according to new research being reported today at the Alzheimer's Association International Conference ® 2025 (AAIC ®), in Toronto and online. The findings highlight the potential of food assistance programs to support cognitive health in the aging population and point to the need for additional efforts to reduce disparities in cognitive aging across different racial and ethnic groups, the researchers said. They also underscore the need for public health policies that ensure equitable access to programs like SNAP, which helps low-income individuals and families buy food, particularly for populations that may face additional barriers to enrollment. Using the nationally representative Health and Retirement Study (HRS), researchers compared participants in SNAP to those who were eligible for the program but didn't participate. They determined that SNAP participants had a 0.10% slower decline in overall cognitive function, or two to three additional years of cognitive health over the 10-year period. "Research has shown that food insecurity can negatively impact cognitive function, and this is one of the first long-term studies to show that food assistance programs can positively impact cognition," said Maria C. Carrillo, Ph.D., Alzheimer's Association chief science officer and medical affairs lead. "Simple, everyday actions can make a difference in brain health and may even lower the risk of Alzheimer's disease and dementia. The Alzheimer's Association is committed to helping all people build these habits into their daily lives, including eating right, one of our 10 Healthy Habits for Your Brain." Researchers analyzed a racially and ethnically representative group of people age 50 and older comparing 1,131 (average age ~63 years) who were enrolled in SNAP in 2010 to 1,216 who were eligible for SNAP but did not participate (average age ~66 years). Memory and executive function — the ability to plan and carry out tasks — were assessed every two years between 2010 and 2020 via telephone or web-based interviews. People with an initial cognition summary score indicating cognitive impairment or dementia (11 or less out of 27 points) were excluded from the analysis. While a 0.10-point difference in annual cognitive decline may seem small, the researchers note that its long-term impact is significant. "For someone starting at a healthy cognitive score, this slower decline could delay reaching the threshold for mild cognitive impairment by nearly a decade," said Linlin Da, MPH, lead author of the study and a Ph.D. candidate in health services research at the University of Georgia, Athens. "This suggests SNAP participation, or another similar nutrition support program, could significantly delay the onset of cognitive impairment or dementia, allowing people to preserve their ability to manage medications, finances and daily tasks longer," said Da. "This ultimately supports greater independence and higher quality of life in older adulthood." "At the same time, we discovered that this protective effect is not the same for everyone: non-Hispanic Black and Hispanic older adults did not benefit as much in cognitive functions compared to non-Hispanic white participants," Da added. Comparing the cognitive findings for White, Black and Hispanic SNAP participants in the study to their peers who didn't participate in SNAP, the researchers found all three groups benefitted, but observed much stronger benefits and slower decline for the White SNAP participants. "We hope health care providers will see that potentially delaying cognitive impairment is another reason to help their patients-in-need secure access to food assistance," said Suhang Song, Ph.D., corresponding author of the study and assistant professor in the department of health policy and management at the University of Georgia College of Public Health. About the Alzheimer's Association International Conference ® (AAIC ®) The Alzheimer's Association International Conference (AAIC) is the world's largest gathering of researchers from around the world focused on Alzheimer's and other dementias. As a part of the Alzheimer's Association's research program, AAIC serves as a catalyst for generating new knowledge about dementia and fostering a vital, collegial research community. AAIC 2025 home page: AAIC 2025 newsroom: AAIC 2025 hashtag: #AAIC25 About the Alzheimer's Association ® The Alzheimer's Association is a worldwide voluntary health organization dedicated to Alzheimer's care, support and research. Our mission is to lead the way to end Alzheimer's and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer's and all other dementia ®. Visit or call 800.272.3900.
